FUNDED GRANTS

SEARCH GRANTS

FROM

TO

YEAR FUNDED

LOCATION

INSTITUTION

RESEARCHER

FILTERS:

From: 2000

Neurolixis

The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.

FUNDED GRANTS (
4)

Promising Outcomes of Original Grant:These researchers are investigating the activity of novel drugs that potently activate serotonin 5-HT1A receptors. Targeting this receptor subtype is an attractive strategy to decrease the dyskinesia that arises in Parkinson's disease (PD) patients from prolonged treatment with levodopa. Data gathered in the previous grant showed that a novel, exceptionally sel...

Study Rationale: The dopamine precursor levodopa is the gold-standard treatment for Parkinson's disease. However, as PD progresses, serotonin neurons increasingly convert levodopa to dopamine as a "false neurotransmitter." This activity underlies the development of troubling levodopa-induced dyskinesia that affects many PD patients. One strategy is to silence the activity of sero...

Promising Outcomes of Original Grant:Researchers investigated the effects of serotonin 5-HT1A biased agonists on rotation behavior in pre-clinical models. The scientists used a pre-synaptic (before impulse is conveyed) 5-HT1A preferential agonist. It stimulated rotation behavior by itself and, at a low dose, this effect was increased by co-administration with levodopa. The effects of the drug were...

Objective/Rationale: Although Parkinson's disease (PD) is primarily caused by dopamine dysfunction, function of serotonin (another neurotransmitter) is also affected. This suggests that serotonergic drugs may address some of the symptoms of PD. The serotonin 5-HT1A receptor is an attractive target because 5-HT1A agonists (chemicals that activate a receptor) are capable of reducing levodopa-induced...